Tuberculosis (TB) is the leading cause of mortality for people living with HIV (PLHIV) worldwide, accounting for nearly one-third of all HIV deaths.1 Although antiretroviral therapy (ART) significantly reduces TB incidence in PLHIV, there is an increased risk of TB during the first months after ART initiation.2 Isoniazid preventive therapy (IPT) reduces all-cause mortality and TB among PLHIV by 32%–62%,3,4 extending beyond the benefit of ART alone.5 The World Health Organization (WHO) thus recommends 36 months of empiric IPT, without diagnostic testing for latent TB infection, for all PLHIV in resource-limited countries without symptoms of active TB.6,7 The 2011 guidelines, however, state that “regular and heavy alcohol use” is a contraindication to IPT, presumably for the concern of increased hepatotoxicity. The WHO also acknowledges that implementation of 36 months of IPT is extremely low; where IPT is implemented, 6-month courses remain predominant.7
Grade 3 or 4 drug toxicity is reported in 0.1%–4.0% of individuals taking isoniazid.8 Alcohol users are considered higher risk, as isoniazid is metabolized by the liver. One observational US study in 1978 reported that daily drinkers had more than 4 times the risk of toxicity compared with nondrinkers,9 but those high toxicity rates are not consistently observed.10 There is also theoretical concern about isoniazid and ART interactions, but higher rates of toxicity with concomitant ART initiation were not observed in trials.5,11
Heavy alcohol consumption, defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria of ≥4 drinks per day or 14 drinks per week for men and ≥3 drinks per day or 7 drinks per week for women, is common among PLHIV. In studies of PLHIV in Sub-Saharan Africa, Brazil, and India, as many as 25% of participants self-reported heavy alcohol consumption.12–15 Current guidance may thus exclude 25% of PLHIV from IPT because of their heavy drinking. In addition, heavy drinking is associated with a 3-fold increase in the risk of TB, slower TB treatment response, and higher mortality on therapy compared with nondrinkers.16–18
We hypothesized that the benefit of a 6-month course of IPT for heavy alcohol drinking PLHIV in high TB-/HIV-burden countries is greater than the elevated risk of grade 3/4 drug toxicity. To investigate, we developed a decision analytic model to compare the risks and benefits of providing IPT for either 6 months or 36 months at the initiation of ART to ART alone for PLHIV who heavily consume alcohol. We validated the model in 3 high TB-/HIV-burden countries—Brazil, India, and Uganda—to further compare the impact of TB prevalence and mortality on the benefit of IPT.
We developed a Markov model to compare ART alone to ART with either 6 or 36 months of empiric IPT for heavy drinking PLHIV enrolling in care in 3 high TB-/HIV-burden countries: Brazil, India, and Uganda (Supplemental Digital Content Figure 1, http://links.lww.com/QAI/B100). We constructed the model using TreeAge Pro 2016 (TreeAge Software Inc., Williamstown, MA). All analyses simulated a closed cohort of PLHIV classified as heavy drinkers by NIAAA criteria initiating ART. The model used a lifetime horizon. Outcomes included life expectancy in years, cumulative TB cases, TB deaths, and fatal and nonfatal toxicity events. We developed inputs to replicate epidemiology, TB incidence, and outcomes specific to each country. We performed 1-and 2-way deterministic sensitivity analyses to evaluate the impact of parameters on model outcomes. To characterize uncertainty around the base case findings, we also performed probabilistic sensitivity analyses. We defined a probability density function around each parameter value and used second-order Monte Carlo simulation to replicate the simulation 1000 times. We reported all results with an associated 95% confidence range.19
The model used a Markov framework with a monthly time cycle. The simulation cohort entered the model and initiated ART either alone or with 6 or 36 months of IPT. During months on IPT, a portion of the cohort experienced symptomatic drug toxicity at which point IPT was discontinued. A portion of IPT toxicity events were fatal. For the 6-month IPT course, we assumed that the IPT protective benefit extended for 6 months beyond therapy after which the incidence of TB returned to that expected without IPT. For the 36-month IPT course, the benefit also extended 6 months beyond therapy, and the risk of IPT toxicity declined over time. The lifetime simulation included 5 health states: (1) alive without TB; (2) alive with TB; (3) alive after treatment of TB; (4) dead, TB attributable; and (5) dead, other causes. In the base case, we assumed no TB relapse after treatment and then relaxed that assumption in sensitivity analyses. The cohort also experienced mortality from causes other than TB, including HIV-related and age-/sex-adjusted non-HIV competing risks of death.
Base Case Parameters
Table 1 summarizes model parameters for cohort characteristics, tuberculosis infection, IPT toxicity and effectiveness, and mortality with ranges used for deterministic sensitivity analyses.
We derived the proportion female for each country from the United Nations Programme on HIV/AIDS country progress reports.20–22 Baseline age was taken as the median age reported in cohort studies of PLHIV initiating ART in each country.23–25
We modeled the relative risk of TB by time on ART such that the probability of developing TB was the highest during the first 3 months of ART.2 We derived a cumulative incidence of TB from country-specific observational data among cohorts initiating ART.2,25–27 The base case assumed no TB relapse after cure, but sensitivity analyses explored TB relapse with rates informed by the American Thoracic Society (ATS) guidelines from 0% to 6% per year.28
IPT Toxicity and Effectiveness
We estimated IPT toxicity among drinkers initiating ART in 2 steps. First, we abstracted the rate of grade 3/4 adverse events in the early ART + IPT arm of the Temprano French National Agency for Research on AIDS and Viral Hepatitis trial.5 Second, to estimate the effect of alcohol use on the risk of IPT toxicity, we identified a cohort study in Botswana that reported IPT hepatotoxicity rates among participants on ART stratified by alcohol dependence characterized by the cut down, annoyed, guilty and eye opener questionnaire.11,29 We applied the risk ratio of 2.37 found in this study to the rate of toxicity observed in Temprano. Because data about the effect of alcohol on IPT toxicity are limited, we developed an additional estimate and report findings for both. For the second estimate, we applied the risk ratio for isoniazid toxicity among daily drinkers in the general population (not PLHIV specific) referenced in the ATS documents (RR = 4.14).8,9 For the 36-month course of IPT, we reduced the probability of developing IPT toxicity after 12 months and again after 24 months. We calculated the risk ratios for relative reductions over time from the adverse event rates reported from 2 clinical sites in Swaziland30,31 and applied these ratios to our base case toxicity estimates. Fatal drug toxicity depended on the development of IPT toxicity. We derived the base case estimate from the Botswana cohort and extrapolated the range for sensitivity analyses from the 95% confidence interval reported by the National Institutes of Health isoniazid drug record.32 We assume that underlying ART toxicity is equivalent in all strategies. To estimate the toxicity attributable to alcohol, we performed sensitivity analyses applying the rate of toxicity events seen in the Temprano French National Agency for Research on AIDS and Viral Hepatitis trial and compared the proportion of toxicity and toxicity deaths to our base case.
We derived the effectiveness of IPT while on therapy from the BOTUSA trial.33 In the 6-month IPT arm, the protective effectiveness of IPT extended for 1 year, 6 months of active therapy plus 6 months of extended benefit, after which participants resumed a monthly risk of developing TB corresponding to the cycle month of the model at that point of time.34–36 Similarly, we extended the benefit of the 36-month IPT course for an additional 6 months.
We derived the case fatality ratio (CFR) for TB by combining a weighted average of the pooled CFR reported in a meta-analysis of HIV-infected patients on ART37 with the CFR reported for HIV-infected patients who default on TB treatment, assuming a 20% defaulter rate in the base case.38
We estimated non-TB mortality, stratified by age, using country-specific life tables.42–44 Because TB-related morality likely affects national-level life expectancy in endemic zones, we adjusted life tables to remove TB mortality. To do so, we estimated the TB attributable mortality rate in each country as the product of prevalence of TB disease × country mortality rate of those with TB. The country mortality rates were extracted from WHO TB reports of each country.39–41 We then subtracted TB attributable mortality rates from the all-cause mortality rates (Supplemental Digital Content Table 1, http://links.lww.com/QAI/B100).
We validated the model in each country against the median life expectancy and cumulative TB incidence.
We performed deterministic 1-way sensitivity analyses for all model parameters. The ranges for deterministic sensitivity analyses were informed by the 95% confidence intervals from observational studies and based on expert opinion when no quantitative measure of uncertainty was available. In the sensitivity analyses for IPT toxicity, we explored a range of toxicity to capture the additional effect of viral hepatitis (B and C) coinfection. For the sensitivity analysis of TB incidence stratified by duration on ART, we used a multiplier to proportionally scale up and down the base case incidence rates while maintaining the trend for decreasing incidence by a longer duration of ART. These analyses not only account for uncertainty in the parameter estimates but also model the increased risk of TB among the heaviest drinkers. We explored a wide range for the TB CFR to simulate excellent treatment retention and effectiveness on one extreme and high default rates or poor treatment effectiveness as may be seen with multi-drug resistant TB cases on the other extreme. For non-TB mortality, we applied a multiplier to proportionally scale up base case background mortality rates to simulate higher mortality at lower CD4 counts. We also assessed parameters to allow for TB relapse after TB treatment completion and varied IPT effectiveness to simulate both poor medication compliance and decreased effectiveness for the prevention of isoniazid-resistant TB.
We constructed tornado diagrams from the 1-way sensitivity analyses of each country to evaluate the impact of model parameters on the life expectancy outcome. For parameters that demonstrated high impact, we performed several 2-way sensitivity analyses. We used threshold sensitivity analyses around the IPT toxicity assumptions to determine the maximum toxicity levels allowable that would favor IPT in each setting.
Last, we conducted probabilistic sensitivity analyses to characterize uncertainty in the simulation results (see Supplemental Digital Content Table 2, http://links.lww.com/QAI/B100). We used the beta distribution to generate probability density functions around each probability parameter based on the counts of events from observational studies. For baseline age and the duration of IPT effect, we assumed a normal distribution of all values specified in the range tested for deterministic sensitivity analyses. For the multiplier variables used to vary TB incidence, IPT toxicity over time, and background non-TB mortality outlined above, we applied a uniform distribution.
The strategy of 6 months of IPT + ART (IPT6) extended life expectancy over both ART alone and 36 months of IPT+ ART (IPT36) in India and Uganda, but neither IPT strategy improved life expectancy in Brazil over ART alone (Table 2). In India, IPT6 extended life expectancy by 0.5 years and IPT36 by 0.3 years. IPT6 reduced TB incidence from 801 TB cases per 1000 persons to 706 cases per 1000 persons and deaths by 12 per 1000 persons, whereas IPT36 further reduced TB incidence to 665 cases per 1000 persons and deaths by 17 per 1000 persons. In Uganda, IPT6 extended life expectancy 0.1 years beyond ART alone, whereas IPT36 reduced life expectancy 0.2 years compared with ART alone. IPT6 reduced TB cases by 82 per 1000 persons and TB deaths by 10 per 1000 persons. ART alone extended life expectancy in Brazil by 0.1 years compared with IPT6 and 0.5 years compared with IPT36. The cumulative cases of TB decreased from 259 cases per 1000 persons on ART to 209 on IPT6 and 193 on IPT36, with 6–8 additional TB fatalities per 1000 persons on ART alone. In all countries, IPT6 resulted in grade 3/4 toxicity in 158–160 per 1000 persons treated, with 8 toxicity deaths per 1000 persons. Between 406 and 415 persons per 1000 treated developed grade 3/4 toxicity in the IPT36 arm, with 20–21 deaths per 1000 treated.
Deterministic Sensitivity Analyses
One-way sensitivity analyses of input parameters are shown in Figure 1 and in the Supplemental Digital Content Figure 2–8, http://links.lww.com/QAI/B100. Parameters with the greatest impact on the risk–benefit ratio of IPT varied by country, with a monthly incidence of TB and a monthly probability of TB death consistently in the top 4 (Supplemental Digital Content Figures 4, 5, and 9, http://links.lww.com/QAI/B100). Fatal and nonfatal IPT toxicity were impactful parameters in Brazil and Uganda, whereas duration of IPT effect superseded fatal IPT toxicity in India. Toxicity and fatal toxicity attributable to alcohol was between 50% and 55.6% (Table 2). The risk benefit favored IPT6 in Brazil when grade 3/4 IPT toxicity was below 0.023 (base case estimate 0.029 and ATS comparator 0.05) and favored IPT36 when toxicity decreased to 0.01 (Fig. 1). The threshold probability of IPT toxicity in India that shifted IPT6 to ART alone was 0.087 (3 times the base case estimate) and 0.044 for IPT36 to ART alone (1.5 times the base case). In Uganda, the strategy shifted against IPT6 to ART alone at a toxicity threshold of 0.044 and against IPT36 to ART alone when the toxicity exceeded 0.02.
The benefit of IPT6 exceeded the risk when the probability of fatal toxicity was less than 0.04 in Brazil, 0.13 in India, and 0.07 in Uganda (base case 0.05 in all countries) (Supplemental Digital Content Figure 6, http://links.lww.com/QAI/B100). The probabilities of fatal toxicity required to shift the results against IPT36 were 0.02 in Brazil, 0.07 in India, and 0.04 in Uganda. Varying the effectiveness of IPT up to 100% did not change the preferred strategy of ART alone in Brazil. When the effectiveness of IPT was below 37% in India, the preferred strategy shifted from IPT36 to no IPT, but the minimal level of effectiveness of IPT needed to shift from favoring IPT6 to no IPT was 4%. In Uganda, the preferred strategy was ART alone if IPT effectiveness was below 49.4% (Supplemental Digital Content Figure 7, http://links.lww.com/QAI/B100).
Two-way sensitivity analyses of the monthly probability of TB death and the incidence of TB during the first 3 months of ART found that the intersection of base case values favored no IPT in Brazil with a narrow margin—small increases in TB mortality or TB incidence shifted the strategy to IPT6. IPT6 was clearly favored in India, and while still favored in Uganda, the margin was narrower (Fig. 2). These trends persisted in 2-way sensitivity analyses of the probability of developing IPT toxicity and the incidence of TB during the first 3 months of ART (Supplemental Digital Content Figure 10, http://links.lww.com/QAI/B100). The intersection point of base case values for each parameter favored IPT6 in India and Uganda, whereas ART alone dominated the strategies in Brazil. However, for the heaviest drinkers, with up to 3 times the greater risk of developing TB, the results favored IPT6 when IPT toxicity was up to twice that of the base case estimate. IPT36 was preferred only with an increased risk of TB along with reduced IPT toxicity, scenarios less likely among the heaviest drinkers.
Probabilistic Sensitivity Analyses
In Brazil, ART alone remained dominant in 51.5% of simulations, whereas IPT6 was selected in 41.1% of the time and IPT36 7.4% (Fig. 3, and Supplemental Digital Content Table 3, http://links.lww.com/QAI/B100). Strategy selection was less robust to uncertainly in India, with IPT6 selected 47.5%, IPT36 27.9%, and ART alone 24.6% of the time. In Uganda, ART alone dominated 44.4% of simulations, whereas the strategy favored IPT6 in 43.2% and IPT36 in 12.4% of simulations.
In this simulation model, the benefits of a 6-month course of IPT at the initiation of ART among heavy drinking PLHIV compared with ART alone outweighed the risks in high TB/HIV prevalence settings, as seen in India and Uganda. The risk benefit of IPT was less in Brazil where TB incidence is lower. Overall, the 36-month course of IPT reduced the cumulative incidence of TB and death compared with the 6-month course of IPT and ART alone in all simulated countries; however, the increased cases of IPT toxicity and deaths that accumulated over the 36-month course negated its benefits beyond the 6-month comparison. The uncertainty in strategy selection seen in probabilistic sensitivity analyses, particularly in Uganda, highlights the need to better characterize IPT toxicity in heavy drinkers.
Global TB and HIV guidelines currently do not reflect the differential impact of IPT in varying country settings that we report. Under conditions of high TB incidence, such as in India and Uganda, IPT toxicity thresholds favoring IPT6 were much higher than our most conservative estimates. These sensitivity analyses also support that IPT benefits are likely to outweigh the increased toxicity risk among heavy drinkers with concomitant viral hepatitis coinfection in high prevalence TB settings. By contrast, data from Brazil showed that in a country with lower TB incidence, the risk of IPT exceeded the benefit unless the true toxicity rate of IPT is 21% less than our base case estimate. The heterogeneity seen between countries suggests that having a single global guideline for IPT among HIV-infected drinkers in resource-limited countries is not optimal.
Although we found that empiric IPT extended life expectancy in many settings, it is clear that strategies to minimize IPT-related morbidity and mortality among drinkers are important for real-world implementation. Instructing patients to stop IPT should symptoms of appetite loss, malaise, or jaundice develop can help prevent hepatic failure and death. Further risk mitigation with liver enzyme monitoring may also prompt discontinuation of therapy before symptom development and irreversible hepatotoxicity. Unfortunately, in settings where IPT is most beneficial, liver enzyme monitoring is often not feasible. However, close to patient diagnostics for liver enzyme monitoring are in development and may make monitoring possible in some settings.45 Another strategy is to better understand the heterogeneity of toxicity risk among drinkers, to which clinical or alcohol use characteristics are associated with complications, and to identify those who could be safely treated.
We note limitations to this analysis. Few studies to date report IPT toxicity stratified by alcohol consumption, and only 1 among PLHIV.11,46–48 Thus, this parameter has the most uncertainty, as it was derived from a combination of trial data and prospective cohort data. The base case estimates may in fact double the count of some alcohol use, as the Temprano trial did not explicitly exclude those who consume alcohol, and the general population toxicity risk may also overestimate, as it is not HIV specific and does not exclude drinkers. We used sensitivity analyses to account for uncertainty in the estimates, and we present toxicity thresholds for whether IPT is favored in each setting.
Second, we included all HIV-infected drinkers and did not investigate providing IPT only for those who have a positive tuberculin skin test (TST), where the benefits of IPT seem to be the greatest.4 However, the TST is not currently part of the WHO guidance6 and often not available in resource-limited settings with high TB burden. Where TB incidence and mortality are lower, screening strategies for latent TB infection such as TST are likely effective to target and treat only those who are infected and decrease unnecessary exposure to IPT toxicity. We also did not simulate TB reinfection or transmission, meaning that our model is conservative in that it does not incorporate the indirect benefit of averted TB transmission. Furthermore, this model strictly evaluated life years gained, cases of TB reduced, and deaths avoided. It did not include utility measures such as health-related quality of life. The comparisons thus did not capture the benefits of improved quality of life among those who avoid TB or the potential decrease in quality of life associated with taking daily medications (ie, for 6 or 36 months). Last, we did not investigate newer regimens, such as 12 weekly doses of rifapentine plus IPT, which have shown promising safety, efficacy, and adherence results49 but are not yet approved for use in developing countries.
Our findings suggest that IPT benefits for PLHIV who heavily consume alcohol outweigh the potential risks of increased drug toxicity where TB incidence and mortality are high and among those with increased TB risk. For countries with lower TB incidence, such as Brazil, IPT toxicity must be lower than our estimates for the benefits to exceed the risks. These results highlight the need for more nuanced recommendations for IPT stratified by TB incidence and/or TB mortality such that countries can implement the policy most applicable to the epidemiology of TB within their borders as opposed to a global one-size-fits-all guideline. Furthermore, there is a clear need for prospective studies of IPT toxicity among PLHIV who consume alcohol. Such data could inform strategies to increase the safety profile for those at the highest toxicity risk instead of current recommendations to withhold beneficial therapy from a substantial proportion of those in greatest need.
1. World Health Organization. Global Tuberculosis
Report 2015. Geneva, Switzerland: World Health Organization; 2015.
2. Liu E, Makubi A, Drain P, et al. Tuberculosis
incidence rate and risk factors among HIV
-infected adults with access to antiretroviral therapy. AIDS. 2015;29:1391–1399.
3. Ayele HT, Mourik MS, Debray TP, et al. Isoniazid
prophylactic therapy for the prevention
infected adults: a systematic review and meta-analysis of randomized trials. PLoS One. 2015;10:e0142290.
4. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis
infection in HIV
infected persons. Cochrane Database Syst Rev. 2010;20:CD000171.
5. Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy
in Africa. N Engl J Med. 2015;373:808–822.
6. World Health Organization. Guidelines for Intensified Tuberculosis
Case Finding and Isoniazid Preventive Therapy
for People Living With HIV
in Resource Constrained Settings. Geneva, Switzerland: World Health Organization; 2011.
7. WHO Guidelines Approved by the Guidelines Review Committee. Recommendation on 36 Months Isoniazid Preventive Therapy
to Adults and Adolescents Living With HIV
in Resource-Constrained and High TB- and HIV
-prevalence Settings: 2015 Update. Geneva, Switzerland: World Health Organization Copyright (c) World Health Organization 2015; 2015.
8. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–952.
9. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid
-related hepatitis: a U.S. public health service cooperative surveillance study. Am Rev Respir Dis. 1978;117:991–1001.
10. Comstock GW. Prevention
among tuberculin reactors: maximizing benefits, minimizing risks. JAMA. 1986;256:2729–2730.
11. Tedla Z, Nyirenda S, Peeler C, et al. Isoniazid
-associated hepatitis and antiretroviral drugs during tuberculosis
prophylaxis in hiv
-infected adults in Botswana. Am J Respir Crit Care Med. 2010;182:278–285.
12. Thakarar K, Asiimwe SB, Cheng DM, et al. Alcohol
consumption in Ugandan hiv
-infected Household-Brewers versus non-Brewers. AIDS Behav. 2016;20:2408–2417.
13. Wandera B, Tumwesigye NM, Nankabirwa JI, et al. Alcohol
consumption among hiv
-infected persons in a large Urban HIV
clinic in Kampala Uganda: a constellation of harmful behaviors. PLoS One. 2015;10:e0126236.
14. Sharma A, Sachdeva RK, Kumar M, et al. Effects of lifetime history of use of problematic alcohol
medication adherence. J Int Assoc Provid AIDS Care. 2014;13:450–453.
15. da Silva CM, Mendoza-Sassi RA, da Mota LD, et al. Alcohol
use disorders among people living with HIV
/AIDS in Southern Brazil: prevalence, risk factors and biological markers outcomes. BMC Infect Dis. 2017;17:263.
16. Rehm J, Samokhvalov AV, Neuman MG, et al. The association between alcohol
use disorders and tuberculosis
(TB). A systematic review. BMC Public Health. 2009;9:450.
17. Volkmann T, Moonan PK, Miramontes R, et al. Tuberculosis
and excess alcohol
use in the United States, 1997–2012. Int J Tuberc Lung Dis. 2015;19:111–119.
18. Amoakwa K, Martinson NA, Moulton LH, et al. Risk factors for developing active tuberculosis
after the treatment of latent tuberculosis
in adults infected with human immunodeficiency virus. Open Forum Infect Dis. 2015;2:ofu120.
19. Neumann PJ, Sanders GD, Russell LB, et al. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2017.
20. UNAIDS. The HIV
and AIDS Uganda Country Progress Report 2014; 2015. Uganda. Available at: http://http://www.unaids.org
21. UNAIDS. The HIV
and AIDS Brazil Country Progress Report; 2015. Brazil. Available at: http://http://www.unaids.org
22. UNAIDS. The HIV
and AIDS India Country Progress Report; 2015. India. Available at: http://http://www.unaids.org
23. Hahn JA, Emenyonu NI, Fatch R, et al. Declining and rebounding unhealthy alcohol
consumption during the first year of HIV
care in rural Uganda, using phosphatidylethanol to augment self-report. Addiction. 2016;111:272–279.
24. Mehta SH, McFall AM, Srikrishnan AK, et al. Morbidity and mortality among community-based people who Inject drugs with a high hepatitis C and human immunodeficiency virus burden in Chennai, India. Open Forum Infect Dis. 2016;3:ofw121.
25. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of anti-retroviral therapy and isoniazid preventive therapy
incidence in HIV
-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441–1448.
26. Alvarez-Uria G, Pakam R, Midde M, et al. Incidence and mortality of tuberculosis
before and after initiation of antiretroviral therapy: an HIV
cohort study in India. J Int AIDS Soc. 2014;17:19251.
27. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis
-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21:713–719.
28. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention
/Infectious Diseases Society of America: treatment of tuberculosis
. Am J Respir Crit Care Med. 2003;167:603–662.
29. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1984;252:1905–1907.
30. Muller Y. Implementation of 36 Months of Isoniazid Preventive Therapy
for Patients Living With HIV
/AIDS in Two Clinics of Shiselwini Region, Kingdom of Swaziland: Medecins Sans Frontieres; 2016. Available at: http://http://www.shrswaziland.com
31. Mueller Y, Mpala Q, Kerschberger B, et al. Adherence, tolerability, and outcome after 36 months of isoniazid
-preventive therapy in 2 rural clinics of Swaziland: a prospective observational feasibility study. Medicine (Baltimore). 2017;96:e7740.
32. National Institutes of Health. LiverTox: isoniazid
. Clinical and Research Information on drug-Induced liver toxicity. Available at: https://livertox.nih.gov
.htm. Accessed June 21, 2016.
33. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid
preventive treatment for tuberculosis
in adults with HIV
infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:1588–1598.
34. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis
infection in HIV
-infected adults. AIDS. 2001;15:2137–2147.
35. Sumner T, Houben RM, Rangaka MX, et al. Post-treatment effect of isoniazid preventive therapy
incidence in HIV
-infected individuals on antiretroviral therapy. AIDS. 2016;30:1279–1286.
36. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid
plus antiretroviral therapy to prevent tuberculosis
: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–690.
37. Odone A, Amadasi S, White RG, et al. The impact of antiretroviral therapy on mortality in HIV
positive people during tuberculosis
treatment: a systematic review and meta-analysis. PLoS One. 2014;9:e112017.
38. Korenromp EL, Bierrenbach AL, Williams BG, et al. The measurement and estimation of tuberculosis
mortality. Int J Tuberc Lung Dis. 2009;13:283–303.
39. World Health Organization. Tuberculosis
Profile. Uganda. Geneva, Switzerland: World Health Organization; 2015.
40. World Health Organization. Tuberculosis
Profile. India. Geneva, Switzerland: World Health Organization; 2015.
41. World Health Organization. Tuberculosis
Profile. Brazil. Geneva, Switzerland: World Health Organization; 2015.
42. World Health Organization. Life Table. Uganda. Geneva, Switzerland: World Health Organization; 2015.
43. World Health Organization. Life Table. India. Geneva, Switzerland: World Health Organization; 2015.
44. World Health Organization. Life Table. Brazil. Geneva, Switzerland: World Health Organization; 2015.
45. Jain S, Rajasingham R, Noubary F, et al. Performance of an optimized paper-based test for rapid visual measurement of Alanine Aminotransferase (ALT) in fingerstick and venipuncture samples. PLoS One. 2015;10:e0128118.
46. Bliven-Sizemore EE, Sterling TR, Shang N, et al. Three months of weekly rifapentine plus isoniazid
is less hepatotoxic than nine months of daily isoniazid
for LTBI. Int J Tuberc Lung Dis. 2015;19:1039–1044; i–v.
47. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid
hepatotoxicity associated with treatment of latent tuberculosis
infection: a 7-year evaluation from a public health tuberculosis
clinic. Chest. 2005;128:116–123.
48. LoBue PA, Moser KS. Use of isoniazid
for latent tuberculosis
infection in a public health clinic. Am J Respir Crit Care Med. 2003;168:443–447.
49. Pease C, Hutton B, Yazdi F, et al. Efficacy and completion rates of rifapentine and isoniazid
(3HP) compared to other treatment regimens for latent tuberculosis
infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17:265.